Anderson, 56, will take on the title of chairman of Bayer's board of management and replace Baumann, who had come under fire for a declining stock price following the company's 2018 acquisition of seeds and pesticides maker Monsanto for about $63 billion.
Anderson was senior vice president of Genentech's immunology and ophthalmology business unti from 2006 to 2010 and senior vice president of its bio-oncology business unit from 2010 to 2013. He also has worked at Biogen in various roles in Cambridge, Massachusetts, and London, ending as as vice president and general manager of the neurology business unit, as business development/marketing manager of Raychem Corp. in the Bay Area and an engineer at Ethyl Corp. in Europe.
Anderson actually will join Bayer April 1 working with Baumann, who has been with Bayer for 35 years, in transition.